BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 15755628)

  • 1. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA; Mossman S; Nairn N; Cheever MA
    Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 peptide vaccine for the treatment of cancer.
    Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
    Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
    Jäger D; Jäger E; Bert F; Knuth A
    Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
    [No Abstract]   [Full Text] [Related]  

  • 10. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA; Sondak VK
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma vaccines: achievements and perspectives.
    Brichard VG; Gérard C
    Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies and vaccines--hope or illusion?
    Jäger D; Knuth A
    Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.